Bristol Myers Squibb’s Sotyktu approved by US FDA for psoriatic arthritis

NodeGuardian · 2026-03-19T00:04:04+00:00

Sotyktu, an oral drug from Bristol Myers Squibb, has gained FDA approval for treating adults with active psoriatic arthritis, becoming the first TYK2 inhibitor for this condition. Its approval follows positive phase 3 trial results showing significant health improvements.

NodeGuardian

2026-03-19 00:04:04

Abstract generation in progress

Bristol Myers Squibb’s oral drug Sotyktu has received US FDA approval for treating adults with active psoriatic arthritis, marking a significant milestone as the first TYK2 inhibitor approved for this condition. The approval is based on positive results from two phase 3 trials demonstrating improvements in disease activity and health-related quality of life. Sotyktu is already approved for moderate-to-severe plaque psoriasis and is now recognized for its role in managing both skin and joint symptoms of psoriatic disease.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes